Cravath, Swaine & Moore LLP Logo
  • Practices
  • People
  • Careers
  • News & Insights
  • Practices
  • People
  • Careers
  • News & Insights
  • Our Story
  • The Cravath System
  • Diversity & Inclusion
  • Pro Bono
  • Alumni Journal
  • 200.Cravath

Cravath’s London Office Moves to 100 Cheapside

Read More

News & Insights

John Buretta Authors Chapter in Global Investigations Review’s Sixth Edition of “The Practitioner’s Guide to Global Investigations”

January 27, 2022

Cravath partner John D. Buretta authored a chapter on cooperating with U.S. authorities during a government investigation in Global Investigations Review’s sixth edition of “The Practitioner’s Guide to Global Investigations,” which published in January 2022.

The chapter, entitled “Co‑operating with the Authorities: U.S. Perspective,” was featured in “Volume I: Global Investigations in the United Kingdom and the United States” and co‑authored by Cravath practice attorney Megan Y. Lew. It analyzes how U.S. government authorities define cooperation, the risks and benefits of cooperation and unique challenges presented in multi‑agency and cross‑border investigations.

Please click here to read the chapter.

Related Practices & Industries

  • Litigation
  • Investigations and Regulatory Enforcement

Authors

Photo
Name
John D. Buretta
Title
Litigation
Title
Partner
Email
jburetta@cravath.com
Phone
+1-212-474-1260
vCard
Download vCard

    Education

    • J.D., 1996, Georgetown University Law Center
      cum laude
    • B.A., 1993, University of California, Berkeley

    Admitted In

    • New York
    • District of Columbia
    Photo
    Name
    Megan Y. Lew
    Title
    Litigation
    Title
    Of Counsel
    Email
    mlew@cravath.com
    Phone
    +1-212-474-1428
    vCard
    Download vCard

      Education

      • J.D., 2010, New York University School of Law
        cum laude
      • B.S., 2004, Cornell University
        magna cum laude

      Admitted In

      • New York

      Related News & Insights

      Deals & Cases

      August 24, 2021

      Exyte’s Acquisition of Critical Process Systems Group

      On August 24, 2021, Exyte Group (“Exyte”) and Wynnchurch Capital announced that they had reached an agreement for an all-share acquisition of Critical Process Systems Group, a group of manufacturing and design companies, by Exyte, a global leader in the design, engineering, and delivery of high-tech facilities. Cravath is representing Exyte in connection with the transaction.

      Deals & Cases

      August 17, 2021

      Nomura International Wins Appeal Affirming Dismissal of Putative Antitrust Class Action

      On July 19, 2021, the U.S. Court of Appeals for the Second Circuit affirmed the district court’s dismissal of a second consolidated amended class action complaint alleging a violation of Section 1 of the Sherman Act as to Cravath client Nomura International plc and several other defendants.

      Deals & Cases

      July 30, 2021

      Swvl’s Business Combination with Queen’s Gambit Growth Capital

      On July 28, 2021, Swvl Inc. (“Swvl”), a Dubai‑based provider of transformative mass transit and shared mobility solutions, and Queen’s Gambit Growth Capital, the first special purpose acquisition company entirely led by women, announced that they have entered into a definitive agreement for a business combination that would result in Swvl becoming a publicly listed company. Upon completion of the proposed transaction, the combined public company will be named Swvl Holdings Corp and is expected to be the first $1 billion plus “unicorn” from the Middle East to list on NASDAQ, under the ticker symbol “SWVL”. Cravath is representing Swvl in connection with the transaction.

      Deals & Cases

      April 12, 2021

      DiaSorin’s $1.8 Billion Acquisition of Luminex Corporation

      On April 11, 2021, DiaSorin S.p.A. (“DiaSorin”), a leading global diagnostics company, announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation (“Luminex”), a leader in multiplexing technology, for a price of $37.00 per share in an all‑cash transaction corresponding to an enterprise value of approximately $1.8 billion. Cravath is representing DiaSorin in connection with the transaction.

      Cravath Bicentennial

      Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.

      Explore

      Cravath, Swaine & Moore LLP Logo
      • CONTACT US
      • OUR STORY
      • ALUMNI PORTAL
      • DISCLAIMERS & NOTICES

      Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.